IMRN - Immuron Limited

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Immuron Limited

62 Lygon Street
Level 3
Carlton, VIC 3053
Australia
61 3 9824 5254
http://www.immuron.com.au

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter AnastasiouExec. Vice ChairmanN/AN/A1960
Dr. Jerry Kanellos Ph.D.Chief Operating OfficerN/AN/A1961
Dr. Gary S. JacobCEO & DirectorN/AN/A1947
Mr. Phillip Allen HainsCFO & Company Sec.N/AN/A1959
Mr. David LyonHead of MarketingN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travelers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease. The company is also developing IMM-529, a clinical stage product for clostridium difficile infections. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research to develop a vaccine for a form of dysentery; and US Naval Medical Research Center to test the reactivity and therapeutic effectiveness of Travelan against Campylobacter and enterotoxigenic escherichia coli. Immuron Limited was founded in 1994 and is headquartered in Carlton, Australia.

Corporate Governance

Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.